book a demo
Home > What is Microfluidic Diffusional Sizing (MDS) Technology?
Microfluidic diffusion technology (MDS) brings a new tool to the analytical characterization toolbox: a different approach that enables the analysis of protein interactions close to in vivo conditions.
Scientists can now determine affinity of interaction (KD), concentration of bound protein, and stoichiometric information, in solution, and all in a single experiment, whether using simple biological buffer systems or complex backgrounds such as serum, plasma and cell lysates.
Watch the video below to understand how Microfluidic Diffusional Sizing works:
MDS enables the quantification of protein interactions in complex backgrounds, providing independent information on affinity, concentration, on-target / off-target binding, and stoichiometry. This information complements data obtained from other characterization techniques, ensuring a better understanding of a protein interaction and its influencing factors. By enabling scientists to go beyond simple studies of KD and concentration, MDS facilitates more informed decisions, from basic research through to therapeutic development.
Microfluidic diffusional sizing (MDS) exploits the unique properties of “flow” in microfluidic channels — specifically laminar flow, where streams can flow alongside one another with no convective mixing. MDS measures molecular size (hydrodynamic radius), and changes in size indicate binding events.
A more detailed description of how MDS works can be found here.
MDS measurements are captured using the Fluidity One Platform.
‘[MDS] is the breakthrough that gives us invaluable new insights & could be a game-changer for our ability to understand, diagnose & treat COVID-19’
‘[MDS] provided an unprecedented level of granularity to identify the mode of action by which SARS-CoV-2 variants spike escape humoral immune response’
‘Microfluidic diffusional sizing allowed us to obtain unique information that helped us elucidate, for the first time, key differences between the way that four anti-Abeta antibody therapeutics bind to different forms of their targets’
Quantify and characterize any protein interaction – even in complex backgrounds, even with challenging targets
Antibody-affinity profiling in serum – SARS-COV-2 anti-spike S1 antibody against SARS-CoV-2 RBD (receptor binding domain)
Antibody-affinity profiling – SARS-COV-2 anti-spike S1 antibody against SARS-CoV-2 RBD
Immunoprofiling in serum during infection – Characterizing the immune response to viral infections
A collaboration with Prof. Adriano Aguzzi and Prof. Tuomas Knowles.
PD-1/PD-L1 interaction – critical in control of autoimmune response
A comparison of binding affinity values for PD-1/PD-L1 from a range of biophysical techniques
KD of aptamer-protein interactions
Follow changes in hydrodynamic radius in solution: Protein A:IgG interaction
Complete the form below to register your interest in the Fluidity One platform.
even in complex backgrounds or with challenging targets